Fortress Biotech, Inc. (FBIO)
Automate Your Wheel Strategy on FBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including FBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FBIO
- Rev/Share 2.2868
- Book/Share 2.3926
- PB 1.6387
- Debt/Equity 1.2225
- CurrentRatio 2.1918
- ROIC -0.688
- MktCap 104287468.0
- FreeCF/Share -2.4276
- PFCF -1.5768
- PE 22.96
- Debt/Assets 0.3765
- DivYield 0
- ROE 0.1102
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of $205 million upon the closing of the transaction.
Read More
Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for gross proceeds of $205 million upon the closing of the transaction.
Read More
Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
Published: February 23, 2026 by: GlobeNewsWire
Sentiment: Neutral
ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe disease is a rare, inherited lysosomal storage disorder …
Read More
Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Fortress Biotech (FBIO) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.43 per share. This compares to a loss of $0.76 per share a year ago.
Read More
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity position, dosed first patients in its two randomized, double-blind, multicenter global Phase 3 trials, the RUBY study (NCT07089875) and the TOPAZ study (NCT07089888), evaluating dotinurad, a next-generation, once daily oral, URAT1 inhibitor with potential for best-in-class safety and efficacy for the treatment of gout.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortress Biotech Inc. - FBIO
Published: October 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fortress Biotech Inc. ("Fortress" or the "Company") (NASDAQ: FBIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Fortress Biotech Investigated by the Portnoy Law Firm
Published: October 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fortress Biotech Inc., ("Slide" or the "Company") (NASDAQ: FBIO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Read More
INVESTOR ALERT: Investigation of Fortress Biotech, Inc. (FBIO) Announced by Holzer & Holzer, LLC
Published: October 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Fortress Biotech, Inc. (“Fortress” or the “Company”) (NASDAQ: FBIO) complied with federal securities laws. On October 1, 2025, Fortress and its subsidiary, Cyprium Therapeutics, Inc., announced that the FDA issued a Complete Response Letter (“CRL”) relating to the New Drug Application (“NDA”) for CUTX-101 and that the “CRL noted cGMP deficiencies had been observed at the facility where CUTX-101 is manufactured.” Following this news, the price of the Company's stock dropped.
Read More
Journey Medical Corporation to Present at the Emerging Growth Conference
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.
Read More
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Published: July 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 …
Read More
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Read More
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Read More
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Published: May 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl)
Read More
New Strong Sell Stocks for May 16th
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Negative
FBIO, AFCG and HRZN have been added to the Zacks Rank #5 (Strong Sell) List on May 16, 2025.
Read More
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Fortress Biotech (FBIO) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.03 per share a year ago.
Read More
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - CFO Srinivas Sidgiddi - VP, R&D Louis Donati - Director, Market Access Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - ROTH Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
Read More
About Fortress Biotech, Inc. (FBIO)
- IPO Date 2011-11-17
- Website https://www.fortressbiotech.com
- Industry Biotechnology
- CEO Lindsay Allan Rosenwald
- Employees 101